Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2005-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JAC/DKI178PMID 15917284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of Caspofungin against Central Nervous System Aspergillus fumigatus Infection in Mice Determined by TaqMan PCR and CFU Methods

  2005cited by this paper
• Efficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis

  2004cited by this paper
• Efficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis

  2004influential reference
• Comparative Efficacies of Four Amphotericin B Formulations—Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet—against Systemic Murine Aspergillosis

  2004cited by this paper
• Efficacy of Amphotericin B or Itraconazole in a Murine Model of Central Nervous System Aspergillus Infection

  2003cited by this paper
• Caspofungin.

  2003cited by this paper
• Problems in dealing with missing data and informative censoring in clinical trials

  2002cited by this paper
• Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia

  2002cited by this paper
• The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro

  2002cited by this paper
• Development of a murine model of cerebral aspergillosis.

  2002cited by this paper
• Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans.

  2002cited by this paper
• fos-1, a putative histidine kinase as a virulence factor for systemic aspergillosis.

  2002cited by this paper
• Safety and tolerability of caspofungin acetate in the treatment of fungal infections

  2002cited by this paper
• Hitting a new target with echinocandins. Why chase something else?

  2001cited by this paper
• Quantitative PCR Assay To MeasureAspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate

  2001cited by this paper
• Treatment strategies for Aspergillus infections.

  2000cited by this paper
• Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

  2000cited by this paper
• Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice

  2000cited by this paper
• Practice Guidelines for Diseases Caused by Aspergillus

  2000cited by this paper
• Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

  2000cited by this paper
• Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of Aspergillus fumigatus with Reduced Susceptibility to Amphotericin B

  1999cited by this paper
• Worst-rank score analysis with informatively missing observations in clinical trials.

  1999cited by this paper
• In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?

  1998cited by this paper
• Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

  1998cited by this paper
• Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.

  1997cited by this paper
• Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis

  1997cited by this paper
• Diagnosis and management of invasive aspergillosis.

  1996cited by this paper
• Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.

  1996cited by this paper
• Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex.

  1995cited by this paper
• Efficacy of oral saperconazole in systemic murine aspergillosis.

  1995cited by this paper
• Treatment of invasive aspergillosis.

  1994cited by this paper
• Quantitative preservation of viability of Aspergillus fumigatus.

  1992cited by this paper
• Amphotericin B lipid complex therapy of experimental fungal infections in mice

  1991cited by this paper
• Unusual lipid structures selectively reduce the toxicity of amphotericin B.

  1988cited by this paper
• Infectious Diseases Society of America

  1969cited by this paper

• Comparative overview of Aspergillus fumigatus, A. flavus, and A. niger: Pathogenicity, resistance, and public health significance.

  2025cites this paper
• Preclinical Models for Cryptococcosis of the CNS and Their Characterization Using In Vivo Imaging Techniques

  2024cites this paper
• Development of a murine model to study the cerebral pathogenesis of Aspergillus fumigatus

  2023cites this paper
• Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis

  2022cites this paper
• Animal Models of Aspergillosis.

  2018cites this paper
• Animal Models of Aspergillosis.

  2018cites this paper
• Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization

  2017influential citation
• CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

  2016cites this paper
• Animal Models to Evaluate Anti-infective Pharmacodynamics

  2016cites this paper
• Combination Therapy for Invasive Aspergillosis: Controversies and Conclusions

  2015cites this paper
• Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis.

  2013cites this paper
• Invasive aspergillosis: new insights into disease, diagnostic and treatment.

  2013influential citation
• Experimental Central Nervous System Aspergillosis Therapy: Efficacy, Drug Levels and Localization, Immunohistopathology, and Toxicity

  2012cites this paper
• In vitro susceptibility of Aspergillus spp. to dithiocarbamate organoruthenium compounds

  2011cites this paper
• Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.

  2011cites this paper
• [Antifungal combination therapy in invasive fungal infections].

  2010cites this paper
• Cerebral Aspergillus Infections and Meningitis

  2009cites this paper
• Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus

  2009cites this paper
• Cerebral aspergillosis: tissue penetration is the key.

  2009cites this paper
• Amphotericin B lipid preparations: what are the differences?

  2008cites this paper
• Associations antifongiques dans les candidoses et aspergilloses invasives

  2008cites this paper
• Associations antifongiques dans les candidoses et aspergilloses invasives Antifungal combination therapy in invasive candidiasis and aspergillosis

  2008cites this paper
• Animal models: an important tool in mycology

  2007cites this paper
• The pharmacology and clinical use of caspofungin

  2007cites this paper
• Fungal infections of the central nervous system: A review of fungal pathogens and treatment.

  2007cites this paper
• Copyright of Informa UK Ltd. Printing and distribution strictly prohibited

  2007cites this paper
• CNS pharmacokinetics of antifungal agents

  2007cites this paper
• CNS pharmacokinetics of antifungal agents.

  2007cites this paper
• A model of cerebral aspergillosis in non-immunosuppressed nursing rats

  2007cites this paper
• Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.

  2006cites this paper
• Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions

  2006cites this paper
• Emerging echinocandins for treatment of invasive fungal infections

  2006cites this paper
• Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them?

  2006cites this paper
• Efficacy of Caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans

  2006cites this paper
• Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.

  2006influential citation
• Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?

  2006cites this paper
• Combination antifungal therapy for invasive aspergillosis - Is it indicated?

  2006cites this paper